|
|
 |
|
Viewing report
|
|
|
|
The National Institute of Clinical Excellence in CNS: A Major Impact on the European Market
Datamonitor, Nov 2002, Pages: 31
The National Institute of Clinical Excellence (Nice) is a regulatory body set up by the UK government in 1999. Nice is responsible for providing guidance on the usage of new technologies and how specific diseases should be treatment managed. Its clinical guidance can dramatically alter the dynamics of a particular market, with a positive approval from Nice likely to result in a significant increase in the revenues that particular compound will get from the UK and the European market.Detailed analysis of the establishment of Nice, its aims, authority and methodologiesIn-depth profiles of the guidance published for Cox-ii inhibitors, Alzheimer’s disease, multiple sclerosis, smoking cessation and schizophreniaDatamonitor strategic recommendations regarding how competing pharmaceutical manufacturers should react to these decisionsAn analysis of what impact Nice has had on different aspects of the healthcare system, such as budgetary considerations and physician independenceA focus upon the impact of Nice in markets outside the UK and what areas in CNS the Institute will be providing guidance upon in the near futureNice guidance has also resulted in changes to the wider healthcare system which pharmaceutical companies can take advantage of to increase revenues.The impact of Nice is being increasingly felt across Europe, meaning that its decisions now affect the commercial performance of drugs in markets outside the UK market.Understand the key dynamics behind Nice and what is its remitEnhance your knowledge about the influence of Nice on various aspects of the UK and European healthcare marketDiscover what different impacts Nice has had in specific CNS marketsEvaluate the clear need to develop multiple strategies to deal with pending Nice decisions
Customers who bought this item also bought
The CNS Market Outlook to 2010
The Outlook For Niche CNS Disorders: Commercial Opportunities In Developing Markets
Healthcare Review: CNS - October 2002
Healthcare Review: CNS - September 2002
Strategies And Tactics That Improve Patient Recruitment and Retention in Clinical Studies
PharmaWatch: CNS
PharmaWatch: CNS
The Future of Personalized Medicine: The Impact of Proteomics on Drug Discovery And Clinical Trial Design
|
|
|
|
